2020 Fiscal Year Final Research Report
Research on endothelial heterogeneity in the tumor vasculature and development of new anti-angiogenic therapy
| Project/Area Number |
19K22562
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 50:Oncology and related fields
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-06-28 – 2021-03-31
|
| Keywords | 腫瘍血管内皮細胞 / 血管新生阻害療法 / 細胞多様性 / 薬剤耐性 / 血管内皮幹細胞 |
|---|
| Outline of Final Research Achievements |
In this project, we aimed to identify tumor endothelial cell (EC) heterogeneity by single cell analysis of whole ECs isolated from mouse tumor model. It is believed that all ECs are equal and possess high plasticity and proliferative potential. However, the result of single analysis suggests that they are heterogenous in terms of gene expression and can be clustered to several distinct subpopulations. Interestingly, we found tumor specific EC subpopulation which is not detected in normal tissue. This subpopulation clearly shows different gene expression profile compared to that of any EC subpopulation in normal tissue. We identified several genes which are highly and lowly expressed in this specific EC subpopulation. These genes may be a new target for developing novel anti-angiogenic drugs in the future.
|
| Free Research Field |
腫瘍血管医学
|
| Academic Significance and Societal Importance of the Research Achievements |
高齢化社会を迎えた日本において効果的ながんの治療法の開発は、生活の質を向上させるために取り組むべき重要な課題である。腫瘍が増大するためには、腫瘍を栄養する血管が必要である。この腫瘍血管を標的とした治療薬は既に臨床応用されているが、その効果は未だ不十分である。本研究により、腫瘍血管内皮細胞の多様性が明らかとなり、さらには腫瘍血管に特異的な血管内皮細胞集団を同定することができた。今後、同定した血管内皮細胞を標的とする新たな血管新生阻害剤の開発につながる可能性が期待でき、学術的にも社会的にも意義のある成果を得た。
|
